Keros Therapeutics, Inc. (KROS) Misses Q1 EPS by 14c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics, Inc. (NASDAQ: KROS) reported Q1 EPS of ($1.26), $0.14 worse than the analyst estimate of ($1.12).
For earnings history and earnings-related data on Keros Therapeutics, Inc. (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Goldman Sachs sees refinery exemptions boosting DK cash flow
- Morgan Stanley Upgrades Mitsubishi Chemical Holdings (4188:JP) (MTLHY) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
